AR067420A1 - Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan - Google Patents
Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecanInfo
- Publication number
- AR067420A1 AR067420A1 ARP080102894A ARP080102894A AR067420A1 AR 067420 A1 AR067420 A1 AR 067420A1 AR P080102894 A ARP080102894 A AR P080102894A AR P080102894 A ARP080102894 A AR P080102894A AR 067420 A1 AR067420 A1 AR 067420A1
- Authority
- AR
- Argentina
- Prior art keywords
- irinotecan
- growth factor
- vegf
- endotelial
- antitumoral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Combinaciones antitumorales constituidas por un inhibidor de VEGF (factor de crecimiento vascular endotelial) asociadas a irinotecan terapéuticamente utiles en el tratamiento de enfermedades neoplásicas. Reivindicacion 4: Productos que contienen un inhibidor de VEGF y de irinotecan en el tratamiento de enfermedades neoplásicas como preparacion combinada para una utilizacion simultánea, separada o escalonada en el tiempo en terapia anticancerígena.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0704868A FR2918279B1 (fr) | 2007-07-05 | 2007-07-05 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067420A1 true AR067420A1 (es) | 2009-10-07 |
Family
ID=38961256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102894A AR067420A1 (es) | 2007-07-05 | 2008-07-04 | Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan |
Country Status (24)
Country | Link |
---|---|
US (3) | US20100160233A1 (es) |
EP (1) | EP2173349B1 (es) |
JP (4) | JP2010532335A (es) |
KR (4) | KR20180105261A (es) |
CN (3) | CN101686975A (es) |
AR (1) | AR067420A1 (es) |
AT (1) | ATE500829T1 (es) |
AU (1) | AU2008290442B2 (es) |
BR (1) | BRPI0812835B8 (es) |
CA (1) | CA2693152C (es) |
CY (1) | CY1111675T1 (es) |
DE (1) | DE602008005457D1 (es) |
DK (1) | DK2173349T3 (es) |
ES (1) | ES2362637T3 (es) |
FR (1) | FR2918279B1 (es) |
HR (1) | HRP20110432T1 (es) |
IL (2) | IL203132A (es) |
MX (1) | MX2009013950A (es) |
PL (1) | PL2173349T3 (es) |
PT (1) | PT2173349E (es) |
RS (1) | RS51777B (es) |
RU (1) | RU2471483C2 (es) |
SI (1) | SI2173349T1 (es) |
WO (1) | WO2009024667A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX367615B (es) | 2002-09-06 | 2019-08-28 | Cerulean Pharma Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
EP2344161B1 (en) * | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
ES2354922B1 (es) | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer. |
US20130029909A1 (en) * | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
SG191334A1 (en) | 2011-01-13 | 2013-08-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
TR201909951T4 (tr) | 2014-07-18 | 2019-07-22 | Sanofi Sa | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ515913A (en) * | 1999-06-08 | 2004-01-30 | Regeneron Pharma | Modified chimeric polypeptides with improved pharmacokinetic properties |
KR20040091083A (ko) * | 2002-03-01 | 2004-10-27 | 파마시아 이탈리아 에스.피.에이. | 이리노테칸 히드로클로라이드의 결정성 다형체 |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
WO2005016369A1 (en) * | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
AU2005265071A1 (en) * | 2004-06-18 | 2006-01-26 | Memorial Sloan-Kettering Cancer Center | VEGF inhibitors for the treatment of malignant pleural effusion |
FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
-
2007
- 2007-07-05 FR FR0704868A patent/FR2918279B1/fr active Active
-
2008
- 2008-07-02 RS RS20110215A patent/RS51777B/en unknown
- 2008-07-02 WO PCT/FR2008/000943 patent/WO2009024667A2/fr active Application Filing
- 2008-07-02 ES ES08827826T patent/ES2362637T3/es active Active
- 2008-07-02 AT AT08827826T patent/ATE500829T1/de active
- 2008-07-02 DE DE602008005457T patent/DE602008005457D1/de active Active
- 2008-07-02 PT PT08827826T patent/PT2173349E/pt unknown
- 2008-07-02 AU AU2008290442A patent/AU2008290442B2/en active Active
- 2008-07-02 RU RU2010103781/15A patent/RU2471483C2/ru active Protection Beyond IP Right Term
- 2008-07-02 EP EP08827826A patent/EP2173349B1/fr active Active
- 2008-07-02 CN CN200880023537A patent/CN101686975A/zh active Pending
- 2008-07-02 MX MX2009013950A patent/MX2009013950A/es active IP Right Grant
- 2008-07-02 PL PL08827826T patent/PL2173349T3/pl unknown
- 2008-07-02 KR KR1020187026491A patent/KR20180105261A/ko not_active Application Discontinuation
- 2008-07-02 KR KR1020107000011A patent/KR20100031123A/ko not_active Application Discontinuation
- 2008-07-02 KR KR1020167017056A patent/KR20160079918A/ko not_active Application Discontinuation
- 2008-07-02 CN CN201610141168.3A patent/CN105833244A/zh active Pending
- 2008-07-02 CA CA2693152A patent/CA2693152C/fr not_active Expired - Fee Related
- 2008-07-02 SI SI200830256T patent/SI2173349T1/sl unknown
- 2008-07-02 KR KR1020157010064A patent/KR20150048910A/ko not_active Application Discontinuation
- 2008-07-02 BR BRPI0812835A patent/BRPI0812835B8/pt active IP Right Grant
- 2008-07-02 JP JP2010514042A patent/JP2010532335A/ja active Pending
- 2008-07-02 CN CN201310556556.4A patent/CN103623392A/zh active Pending
- 2008-07-02 DK DK08827826.2T patent/DK2173349T3/da active
- 2008-07-04 AR ARP080102894A patent/AR067420A1/es not_active Application Discontinuation
-
2010
- 2010-01-04 IL IL203132A patent/IL203132A/en active IP Right Grant
- 2010-01-04 US US12/651,767 patent/US20100160233A1/en not_active Abandoned
-
2011
- 2011-06-08 CY CY20111100551T patent/CY1111675T1/el unknown
- 2011-06-09 HR HR20110432T patent/HRP20110432T1/hr unknown
-
2014
- 2014-01-13 US US14/153,795 patent/US20140127202A1/en not_active Abandoned
- 2014-08-29 JP JP2014174963A patent/JP2014240422A/ja active Pending
-
2015
- 2015-08-31 IL IL240965A patent/IL240965A0/en unknown
-
2016
- 2016-11-16 JP JP2016222826A patent/JP2017052789A/ja active Pending
-
2018
- 2018-08-15 JP JP2018152805A patent/JP2019006785A/ja active Pending
-
2019
- 2019-02-11 US US16/272,315 patent/US20190275147A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067420A1 (es) | Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan | |
RS52102B (en) | PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE | |
ECSP12012106A (es) | Terapia antiviral | |
TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
ECSP109934A (es) | Compuesto - 946 | |
UY34358A (es) | ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?. | |
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
MX2014006762A (es) | Metodos para el tratamiento de desordenes cardiovasculares. | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab | |
MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
WO2018102261A3 (en) | Boronic derivatives hydroxamates as anticancer agents | |
AR085132A1 (es) | Composiciones farmaceuticas para el tratamiento de glioma maligno | |
AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
CR20110586A (es) | Combinación antitumoral que comprende cabazitaxel y capecitabina | |
GB201014391D0 (en) | Drug composition and its use in therapy | |
ES2723778T3 (es) | Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos | |
NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
WO2009138507A3 (en) | Anti-cancer combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |